Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aprocitentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 17/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 16/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | TSPO | P30536 | 1/20 | 0.71 |
| ▸ | DRD3 | P35462 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aprocitentan SCHEMBL30439551 | 1.00 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL25646617 | 0.93 | EDNRB (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL3650930 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5101990 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL31266904 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5500351 | 0.88 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL9891388 | 0.87 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL31442652 | 0.86 | EDNRA (0.76) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL17582648 | 0.85 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5494210 | 0.85 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| US-20250340520-A1 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-06 | — | — | US | claimed |
| US-12421214-B2 | Solid state forms of aprocitentan and process for preparation thereof | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-09-23 | — | — | US | claimed |
| EP-4616867-A1 | COMBINATION OF ENDOTHELIN RECEPTOR ANTAGONIST AND GLUCOCORTICOID FOR TREATING IGA NEPHROPATHY | Sanreno Therapeutics (Shanghai) Limited (CN) | 2025-09-17 | — | — | EP | claimed |
| EP-3658140-B1 | COMBINATIONS OF APROCITENTAN WITH FURTHER ACTIVE INGREDIENTS FOR THE TREATMENT OF RESISTANT HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-21 | — | — | EP | claimed |
| US-12297189-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-13 | — | — | US | claimed |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-17 | — | — | US | claimed |
| EP-4532472-A1 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | Idorsia Pharmaceuticals Ltd (CH) | 2025-04-09 | — | — | EP | claimed |
| EP-3716979-B1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-09 | — | — | EP | claimed |
| EP-4529461-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | Idorsia Pharmaceuticals Ltd (CH) | 2025-04-02 | — | — | EP | claimed |
| US-20220296601-A1 | TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX INC (US) | 2022-09-22 | — | — | US | claimed |
| EP-4056182-A1 | CRYSTAL FORM OF APROCITENTAN, PREPARATION METHOD THEREFOR AND USE THEREOF | Crystal Pharmaceutical (Suzhou) Co., Ltd. (CN) | 2022-09-14 | — | — | EP | claimed |
| WO-2022180194-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION | ACTELION PHARMACEUTICALS LTD (CH) | 2022-09-01 | — | — | WO | claimed |
| US-11382915-B2 | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | claimed |
| EP-4014976-A1 | APROCITENTAN FOR USE IN THE TREATMENT OF HYPERTENSION AND RELATED DISEASES IN COMBINATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE) OR ANGIOTENSIN RECEPTOR BLOCKER (ARB) | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-22 | — | — | EP | claimed |
| CN-114630668-A | Aprocitentan crystal form, preparation method and application thereof | 苏州科睿思制药有限公司 | 2022-06-14 | — | — | CN | claimed |
| US-20220096474-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | ACTELION PHARMACEUTICALS LTD. (CH) | 2022-03-31 | — | — | US | claimed |
| US-20210206750-A1 | CRYSTALLINE FORMS OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE APROCITENTAN | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-08 | — | — | US | claimed |
| US-10919881-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-16 | — | — | US | claimed |
| WO-2018154101-A1 | CRYSTALLINE FORMS OF THE 4-PYRIMIDINESULFAMIDE DERIVATIVE APROCITENTAN | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296601-A1 | TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS | REN, CCR2, AGTR2 | EDNRA 8/4885EDNRB 14/4885SLC6A2 2808/4885 |
| US-12297189-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | AGTR2, AGTR1, EDNRA | EDNRA 3/4885EDNRB 5/4885SLC6A2 700/4885 |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | AGTR2, AGTR1, AGT | EDNRA 4/4885EDNRB 5/4885SLC6A2 47/4885 |
| US-11382915-B2 | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists | REN, CCR2, AGTR2 | EDNRA 7/4885EDNRB 12/4885SLC6A2 3121/4885 |
| US-20220096474-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | PDE9A, PDE3A, PTGIS | EDNRA 15/4885EDNRB 58/4885SLC6A2 2452/4885 |
| US-10919881-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | AGTR2, EDNRA, AGTR1 | EDNRA 2/4885EDNRB 4/4885SLC6A2 738/4885 |
| US-12421214-B2 | Solid state forms of aprocitentan and process for preparation thereof | TTR, AGT, CYP4A11 | EDNRA 525/4885EDNRB 1197/4885SLC6A2 202/4885 |
| US-20210206750-A1 | CRYSTALLINE FORMS OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE APROCITENTAN | AGTR2, EDNRA, AGTR1 | EDNRA 2/4885EDNRB 4/4885SLC6A2 738/4885 |
| US-20250340520-A1 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | AGTR1, AGTR2, AGT | EDNRA 4/4885EDNRB 6/4885SLC6A2 87/4885 |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | SLC5A2, SLC5A1, GLP1R | EDNRA 6/4885EDNRB 9/4885SLC6A2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.